News Releases

Feb 8, 2018

Vifor Pharma ferroportin inhibitor enters Phase-I clinical trial

VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
Jan 4, 2018

Avacopan conditional marketing authorization application accepted for regulatory review by European Medicines Agency

Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
Jan 4, 2018

Veltassa® approved for marketing in Switzerland for the treatment of Hyperkalaemia

Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
Nov 23, 2017

Third Global Iron Deficiency Day to Raise Awareness of the Symptoms of Iron Deficiency

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Sep 27, 2017

Vifor Pharma Expands Exclusive License Agreement for the Commercialisation of Mircera® in the Us

PDF VERSION OF PRESS RELEASE Back to overview of Press Releases

Show per page

Filter by Company: